文献速递前列腺癌

68Ga-PSMA PET/CT SUVmax预测中危前列腺癌Gleason模式4及病理升级

68Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography Maximum Standardized Uptake Value as a Predictor of Gleason Pattern 4 and Pathological Upgrading in Intermediate-Risk Prostate Cancer.
PubMed 文献 · J Urol · 2021-09-21

该研究回顾了220例经会阴模板活检为GG2-3的中危前列腺癌患者,其中135例接受手术。68Ga-PSMA PET/CT的SUVmax与高比例Gleason模式4(GP4)及病理升级独立相关,可能改善风险分层。

要点

  • SUVmax在高比例GP4组显著更高(如>50% GP4组5.51 vs 3.31,p<0.001)。
  • SUVmax是>50%和>20% GP4的独立预测因子(OR分别为1.39和1.24)。
  • SUVmax阈值5.4预测病理升级特异性91%、阴性预测值94%。

核心结论

  • 68Ga-PSMA PET/CT的SUVmax与Gleason模式4比例及病理升级相关,可能改善中危前列腺癌的风险分层。

研究设计与样本

  • 回顾性队列研究,纳入2015年11月至2021年1月间经会阴模板活检为GG2-3且行68Ga-PSMA PET/CT的220例男性,其中135例接受手术。

主要发现

  • SUVmax在高GP4组更高:>50% GP4组5.51(IQR 4.19-8.49) vs 3.31(2.64-4.41),p<0.001;>20% GP4组4.77(3.31-7.00) vs 3.13(2.64-4.41),p<0.001;>10% GP4组4.54(6.10-3.13) vs 3.03(2.45-3.70),p<0.001。
  • SUVmax是>50% GP4(OR=1.39 [95%CI 1.18-1.65],p<0.001)和>20% GP4(OR=1.24 [1.04-1.47],p=0.015)的独立预测因子。
  • SUVmax是病理升级(活检GG1/2至手术GG≥3)的独立预测因子(OR=1.22 [1.01-1.48],p=0.036)。
  • SUVmax阈值4.5预测>20% GP4的敏感性85%、特异性58%、阳性预测值75%、阴性预测值72%。
  • SUVmax阈值5.4预测病理升级的特异性91%、阴性预测值94%。

关键数值与推荐

  • 高GP4定义为>50%、>20%或>10% GP4。
  • 病理升级定义为活检GG1/2至手术GG≥3。
  • SUVmax阈值4.5预测>20% GP4的敏感性85%、特异性58%、阳性预测值75%、阴性预测值72%。
  • SUVmax阈值5.4预测病理升级的特异性91%、阴性预测值94%。

临床怎么用

  • 对于中危前列腺癌患者,68Ga-PSMA PET/CT的SUVmax可辅助识别高比例GP4及病理升级风险较高者,帮助优化主动监测决策。

局限性

  • 回顾性研究设计,仅135例接受手术,可能存在选择偏倚。
  • 样本来自单一中心,结果需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Accurate risk stratification remains a barrier for the safety of active surveillance in patients with intermediate-risk prostate cancer. [68Ga]Ga-PSMA-11 prostate-specific membrane antigen positron emission tomography/computerized tomography (68Ga-PSMA PET/CT) and the maximum standardized uptake value (SUVmax) may improve risk stratification within this population. MATERIALS AND METHODS: We reviewed men with International Society for Urological Pathology Grade Group (GG) 2-3 disease on transperineal template biopsy undergoing 68Ga-PSMA PET/CT from November 2015 to January 2021. Primary outcome was the presence of high percentage Gleason pattern 4 (GP4) disease per segment at surgery at 3 thresholds: >/<50% GP4, >/<20% GP4, and >/<10% GP4. SUVmax was compared by GP4, and multivariable logistic regression examined the relationship between SUVmax and GP4. Secondary outcome was association between SUVmax and pathological upgrading (GG 1/2 to GG ≥3 from biopsy to surgery). RESULTS: Of 220 men who underwent biopsy, 135 men underwent surgery. SUVmax was higher in high GP4 groups: 5.51 (IQR 4.19-8.49) vs 3.31 (2.64-4.41) >/<50% GP4 (p <0.001); 4.77 (3.31-7.00) vs 3.13 (2.64-4.41) >/<20% GP4 (p <0.001); and 4.54 (6.10-3.13) vs 3.03 (2.45-3.70) >/<10% GP4 (p <0.001). SUVmax remained an independent predictor of >50% (OR=1.39 [95%CI 1.18-1.65], p <0.001) and >20% (OR=1.24 [1.04-1.47], p=0.015) GP4 disease per-segment, and of pathological upgrading (OR=1.22 [1.01-1.48], p=0.036). SUVmax threshold 4.5 predicted >20% GP4 with 58% specificity, 85% sensitivity, positive predictive value 75% and negative predictive value 72%. Threshold 5.4 predicted pathological upgrading with 91% specificity and negative predictive value 94%. CONCLUSIONS: SUVmax on 68Ga-PSMA PET/CT is associated with GP4. SUVmax may improve risk stratification for men with intermediate-risk prostate cancer.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Xue AL, Kalapara AA, Ballok ZE, et al. 68Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography Maximum Standardized Uptake Value as a Predictor of Gleason Pattern 4 and Pathological Upgrading in Intermediate-Risk Prostate Cancer. J Urol. 2021. PMID: 34546815. doi:10.1097/JU.0000000000002254

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。